It is important to note that the questions and answers below refer to chronic phase CML. Management of accelerated phase, blast crisis or post-transplant should be discussed in detail with the clinical team.
CML EHA SWG 29 MARCH 2020
CML, TKI treatment and COVID-19 disease
Dr Delphine Rea, Saint-Louis University Hospital, Paris, France and Professor Rudiger Hehlmann, ELN/EHA-SWG for CML
Expert Opinion from the NCRI CML Subgroup 17th Mar 2020, updated 27th March 2020
The latest UK government updates are listed here:
This guidance is for people, including children, who are at very high risk of severe illness from coronavirus (COVID-19) because of an underlying health condition, and for their family, friends and carers.
iCMLf only want to hear from patients who have had COVID-19 confirmed by a laboratory test. If you have had symptoms consistent with COVID-19 but have not had it confirmed by a test, please do not get in touch with them and use their valuable time.
Note: CODVID-19 Virus request from International CML Foundation
CML and COVID-19 case collection
Dr Michael Deininger (USA), Dr François Guilhot (France), Dr Jeroen Janssen (Netherlands), Dr Tim Hughes (Australia), Dr Jeffrey Lipton (Canada), Dr Franck Nicolini (France), Dr Jerry Radich (USA), Dr Delphine Rea (France), Dr Giuseppe Saglio (Italy), Dr Suzanne Saussele (Germany), Dr Rick Silver (USA), Dr Juan-Luis Steegmann (Spain)
This NCCN QUICK GUIDE tm sheet summarises key points from the complete
NCCN Guidelines for Patients®: Chronic Myeloid Leukemia. These guidelines explain
which tests and treatments are recommended by experts in cancer. To view and download the guidelines, visit NCCN.org/patients.
https://www.nccn.org/patients/guidelines/content/PDF/nccnquickguide-cml-...
Full NCCN Guidelines for CML 2020:
Thank you to everyone who completed our recent survey investigating App use and functionality in the setting of CML.
We were overwhelmed by the number of responses and our final total of 286 (from every corner of the globe!) was far greater than we had expected.
Our key findings were that just under a quarter of respondents were aware that Apps are available to support patients in managing their CML - however, only 1 in 9 respondents had actually used an App.
Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukaemia (CML). Following these recommendations, survival of CML patients has become very close to normal. The next, ambitious, step is to bring as many patients as possible into a condition of treatment-free remission (TFR).
https://ashpublications.org/bloodadvances/article/3/24/4280/429987/Manag...
Atypical CML, or aCML is a form of CML where there is no expression of the BCR-Abl fusion gene. This has made it difficult to treat.
https://www.targetedonc.com/news/ruxolitinib-shows-noteworthy-responses-...